Jeron Selvain Presents Innovative Regenerative Medicine Technology PDRN at Korean Society for Stem Cell Therapy

Kim Deokgyu, CEO of Geron Selvain, Lecture at the Korean Society for Stem Cell Therapy. Provided by Geron Selvain

Jeron Selvain, a company specializing in the production of prescription pharmaceuticals, announced on November 6 that it participated as a speaker at the "2025 Korean Society for Stem Cell Therapy Fall Academic Conference," where it delivered a lecture on the mechanism of action and clinical application potential of polydeoxyribonucleotide (PDRN) used in regenerative medicine treatments.

This academic conference, hosted by the Korean Society for Stem Cell Therapy, served as a platform for sharing the future direction of stem cell therapy and practical treatment strategies. Medical professionals from across Korea gathered to exchange the latest research trends and clinical experiences in regenerative medicine.

At the conference, Kim Deokgyu, a physician-scientist and CEO of Jeron Selvain, gave a presentation titled "PDRN Beneficial for Regenerative Medicine Treatments." He provided an in-depth discussion on the mechanism of action and clinical applicability of PDRN, which plays a key role in cell therapy and tissue regeneration processes.

In particular, he introduced Jeron Selvain's proprietary patented technology, "Prism Technology Nano PDRN," which enables the production of small and uniform molecules at the nano scale, thereby increasing absorption rates in the body. The company is actively conducting preclinical and clinical research not only in dermatology but also in orthopedics, dentistry, rehabilitation medicine, and various other fields.

Kim Deokgyu, CEO of Jeron Selvain, emphasized, "PDRN is a nucleic acid component extracted from salmon germ cells that promotes tissue regeneration and cell proliferation. It has a structure very similar to human DNA, resulting in fewer side effects and high safety when applied to the human body. Our PDRN, extracted using a low-temperature process, has the advantage of smaller and more consistent molecular weight compared to conventional high-temperature extraction methods, leading to reduced pain."

He added, "Jeron Selvain plans to lead the way in providing sustainable regenerative medicine solutions through ESG-based production processes and a global academic network."

This content was produced with the assistance of AI translation services.